about
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaSmoldering multiple myelomaVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.Smoldering multiple myeloma.Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomideEnoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomideThrombosis in multiple myelomaGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaIterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaDiagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.Dilemmas in treating smoldering multiple myeloma.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsStem cell transplantation for multiple myeloma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Targeted therapy in multiple myeloma.Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.Drug insight: thalidomide as a treatment for multiple myeloma.Angiogenic inhibitors: a new therapeutic strategy in oncology.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Thalidomide in multiple myeloma: past, present and future.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaRole of thalidomide in previously untreated patients with multiple myeloma.Treatment of multiple myeloma in the targeted therapy era.Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).Cancer and thrombosis: implications of published guidelines for clinical practice.Introducing a new entity: chemotherapy-induced arrhythmia.Palliative oncology: thalidomide.Cost-effectiveness of lenalidomide in multiple myeloma.
P2860
Q24619589-65CF1EA7-4DE1-4BF7-AE27-A2000B76BF85Q26863331-FE7DC6D4-3EB5-4293-B564-B6F1A15AF99AQ27008491-D631B0D0-85C3-4A9F-90F2-0B1075BB7078Q27687567-F1B15862-8089-4388-A647-E9CB152253D9Q28082855-EF2A6B46-02F9-4957-865E-BD41F64CE865Q28192646-A1DFEF63-803E-421C-8DA9-557595524AA6Q28199907-ED2EE8EC-C4A1-4162-BB5E-070787E36903Q28219961-E5FEF61A-8482-4E23-9F30-BF2B7D276AE8Q28742668-D10CAB47-936B-47A3-8064-C95589F553C9Q30897960-B5CDBA83-FF3C-400E-A97C-E8C4E23093CDQ33364235-A86FDCEF-C027-4831-9050-EA943F493969Q33389026-976A2D76-5C70-4831-8CD1-62346A5B6396Q33408049-EC27C206-FB93-4193-BD50-C332799EA69DQ33628815-F675D930-108B-47BA-A62D-4414F04E3EB5Q33940841-174200CE-B00D-4FF9-8791-9AD2A10A3A25Q34497797-416911CC-B084-4572-8148-1DDCAB04BE5EQ34557651-FE7C4D7B-7419-46E9-B1CD-95ED51E13CEDQ34716500-5E581108-775F-4E5F-A282-50368BF10F7BQ35026302-37EBAFC5-FEDA-497A-AEC8-24888779AF15Q35298727-04E9A1D1-B03A-4233-93AB-DDA5FD6DDD0FQ35692626-B82FE698-8211-4AAC-B4A1-5B01B665FB97Q36040871-1A70F9B5-1A2B-422E-BA81-6C97BE2DA9C8Q36108614-03FB5A53-7F41-4BB4-A3BD-5CF8D5E991D9Q36132803-6E729906-065B-4944-8141-6E6384FEE480Q36304004-923F5883-117F-4490-BFB4-49FE7AB0F1DCQ36306264-F447A36F-462D-4C47-879B-66200A4491D3Q36407446-B1551598-965A-4DBA-A670-1C489167ED70Q36616493-5F38AA43-6EF8-4649-AE16-3D0E111525FAQ36777247-6B434CF2-9EE8-4FF2-AD8C-9A1F3497A26BQ37038414-C5134830-8874-4738-BBCC-CC535C5B2565Q37148370-25CF48D4-343E-4ACC-A2CA-0C87D89B504DQ37160347-578E9353-F9B5-41AC-AC17-0AD960E21917Q37171994-AD0E1E2B-38E9-4187-8B50-26BB8301FB1CQ37300004-8B0DF2A8-0AD0-4401-A776-595F7E00952AQ37385547-177354E3-7AC5-4059-922F-53281005CD52Q37429722-2D15B35D-0A73-40D6-B156-CF191DAD6551Q37533816-D6541EF0-5284-4087-9EF1-015FBD1F8E2FQ37607920-BF60B62E-B159-4AA2-AA8B-26BFF84CBA2FQ37618475-BBCE1F7F-331B-4F49-AFD6-FB742DFA919FQ37764870-D908667A-F099-4E2C-B540-349834C03A14
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Thalidomide as initial therapy for early-stage myeloma.
@en
Thalidomide as initial therapy for early-stage myeloma.
@nl
type
label
Thalidomide as initial therapy for early-stage myeloma.
@en
Thalidomide as initial therapy for early-stage myeloma.
@nl
prefLabel
Thalidomide as initial therapy for early-stage myeloma.
@en
Thalidomide as initial therapy for early-stage myeloma.
@nl
P2093
P2860
P356
P1433
P1476
Thalidomide as initial therapy for early-stage myeloma.
@en
P2093
Rajkumar SV
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402866
P577
2003-04-01T00:00:00Z